While PPARγ agonists and most of PPARγ target genes are proven protection in type 2 diabetes and cardiovascular diseases, a minority of PPARγ target genes, such as CD36, are reported to promote VSMC proliferation and tumor metastasis48–52. The gene discussed is CD36; the disease is type 2 diabetes mellitus.